SISAF
SiSaf is an RNA delivery and therapeutics company. Its proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon. The company’s Bio-Courier portfolio includes silicon stabilized hybrid lipid nanoparticles (sshLNP) that improve the stability, safety, and transfection efficiency of RNA. SiSaf uses sshLNP to develop a pipeline of RNA therapeutics for rare genetic disorders a... nd is maximizing the potential of its technology through research partnerships. Led by founder and leading biomaterials specialist Dr Suzanne Saffie-Siebert, SiSaf is a venture capital backed private company. Headquartered in Guildford, UK, it has fully integrated research labs and bio-analytical facilities, a scalable technology to fast-track development, and a growing patent estate with extensive freedom to operate.
SISAF
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2008-01-01
Address:
Guildford, Surrey, United Kingdom
Country:
United Kingdom
Website Url:
http://www.sisaf.com
Total Employee:
11+
Status:
Active
Contact:
+44 1483 912002
Total Funding:
28.63 M USD
Technology used in webpage:
SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics Wordpress Plugins Global Site Tag
Similar Organizations
Algologie
Algologie is the standard-setter in the field of natural skin care.
In’Oya
In’Oya is develops dermo-cosmetic products derived from a patented technology, without any side effects, intended for pigmented skin.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
STENDERS
STENDERS produces and sells showering, bathing, and body care products.
Subitec
Subitec is engaged in the production of microalgae biomass substances for the cosmetics and food additives industries.
Current Advisors List
Board_member
2018-07-30
Board_member
2016-08-31
Board_member
2016-07-01
Board_member
2018-07-30
Board_member
2016-07-06
Board_member
2008-11-12
Current Employees Featured
Suzanne Saffie-Siebert Chairwoman and CEO @ SiSaf
Chairwoman and CEO
2016-07-01
Michael Welsh Chief Scientific Officer @ SiSaf
Chief Scientific Officer
2017-01-01
Richard Scarrott Chief Financial Officer @ SiSaf
Chief Financial Officer
2019-08-19
Nissim Torabi-Pour Chief Technical Officer @ SiSaf
Chief Technical Officer
2016-01-01
Spiros Servos Head of Business Development @ SiSaf
Head of Business Development
2019-12-20
Charles Weatherstone Chief Marketing Officer @ SiSaf
Chief Marketing Officer
2017-01-01
Founder
Investors List
Vickers Venture Partners
Vickers Venture Partners investment in Series B - SiSaf
Vickers Venture Partners
Vickers Venture Partners investment in Series A - SiSaf
Croda International
Croda International investment in Corporate Round - SiSaf
XNSI Sisaf Holdings LLC
XNSI Sisaf Holdings LLC investment in Series A - SiSaf
Innovation Ulster
Innovation Ulster investment in Series A - SiSaf
Vickers Venture Partners
Vickers Venture Partners investment in Series A - SiSaf
Invest Northern Ireland
Invest Northern Ireland investment in Series A - SiSaf
Vickers Venture Partners
Vickers Venture Partners investment in Series A - SiSaf
Vickers Venture Partners
Vickers Venture Partners investment in Series A - SiSaf
XNSI Sisaf Holdings LLC
XNSI Sisaf Holdings LLC investment in Series A - SiSaf
Official Site Inspections
http://www.sisaf.com
- Host name: 199.16.173.142
- IP address: 199.16.173.142
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "SiSaf"
ABOUT US - SiSaf Ltd
During SiSaf’s foundational years a small team worked on developing and optimising the new hybrid technology and generating safety and efficacy data. These data enabled SiSaf in 2016 to secure Series A funding to pivot from a …See details»
SiSaf - Crunchbase Company Profile & Funding
SiSaf uses sshLNP to develop a pipeline of RNA therapeutics for rare genetic disorders and is maximizing the potential of its technology through research partnerships. Led by founder and …See details»
SiSaf Company Profile 2024: Valuation, Funding
When was SiSaf founded? SiSaf was founded in 2006. Where is SiSaf headquartered? SiSaf is headquartered in Guildford, United Kingdom. What is the size of SiSaf? SiSaf has 23 total employees. What industry is SiSaf in? SiSaf’s …See details»
SiSaf Ltd - The Org
SiSaf is an RNA delivery and therapeutics company. Its proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of …See details»
Member profile: SiSaf Ltd | BIA
Led by founder and leading biomaterials specialist Dr. Suzanne Saffie-Siebert, SiSaf is a venture capital-backed private company. Headquartered in Guildford, UK, it has fully integrated …See details»
SiSaf Ltd. - Drug pipelines, Patents, Clinical trials - Synapse - Patsnap
Explore SiSaf Ltd. with its drug pipeline, therapeutic area, technology platform, 10 news, and 8 literature, Disease Domain:Endocrinology and Metabolic Disease, Neoplasms, Technology …See details»
SiSaf Ltd | BIO-Europe - Informa Connect
SiSaf’s Bio-Courier technology combines a proprietary bioabsorbable silicon matrix with surface lipids and amino acids, a structure that addresses several of the major limitations and …See details»
XNSI Sisaf Holdings LLC - Crunchbase
Jul 2, 2018 SiSaf raised $3,500,000 / Series A from Vickers Venture Partners and XNSI Sisaf Holdings LLC. Discover more funding rounds . Details. Edit Details Section. Operating Status …See details»
SiSaf Ltd Announces US$13.2 Million Series B Financing
Nov 26, 2020 SiSaf Ltd announced today that it has raised US$13.2 million in Series B financing. This funding round was led by Vickers Venture Partners and matched by the UK …See details»
SiSaf Company Profile - Office Locations, Competitors, Revenue
SiSaf Summary. Company Summary. Overview. SiSaf is a drug development company. It provides ProSilic, a biodegradable hybrid of porous silicon and liposomes designed to take …See details»
SiSaf - Company info. interviews, news - biopharmatrend.com
May 16, 2023 FDA Recognizes SiSaf's siRNA Therapy, SIS-101-ADO, for Autosomal Dominant Osteopetrosis Treatment May 16, 2023 In a noteworthy development in the pharmaceutical …See details»
SiSaf’s Innovative RNA Therapeutic for Rare Genetic Skeletal …
Oct 12, 2022 LINTHICUM HEIGHTS, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- SiSaf Ltd, an RNA delivery and therapeutics company, announces that it is initiating the U.S. FDA …See details»
SiSaf’s Bio-Courier Technology Enables Clinical Trial Success for ...
Jun 10, 2024 SiSaf Ltd. Positive topline results in a Phase II clinical trial of a licensee’s alopecia treatment using the ProSilic ® variant of SiSaf’s Bio-Courier ® delivery technology. …See details»
SiSaf exercises its option under licencing agreement on gene …
Nov 4, 2021 SiSaf is now committed to developing SiS-101-ADO2 for the treatment of autosomal dominant osteopetrosis type 2 and is preparing data for its IND package with the aim of …See details»
PIPELINE - SiSaf Ltd
SiSaf is developing a growing pipeline of RNA therapeutics, with a current focus on rare skeletal disorders. Our lead program is a siRNA treatment of Osteopetrosis ADO2. These therapeutics …See details»
SiSaf's Innovative RNA Therapeutic for Rare Genetic Skeletal …
Oct 12, 2022 SiSaf's proprietary Bio-Courier® technology is an innovative delivery platform designed to accelerate the technical advances and application of promising RNA therapeutics.See details»
SiSaf’s Bio-Courier Technology Enables Clinical Trial
Oct 6, 2024 SiSaf is an RNA therapeutics company with a proprietary delivery platform. Its lead programs are a siRNA treatment for Osteopetrosis ADO2 and a partnered siRNA treatment for …See details»
Our Enabling Technology - SiSaf Ltd
SiSaf’s Bio-Courier technology addresses the challenges of lipid nanoparticles by stabilizing both lipids and RNA through a bioabsorbable silicon matrix. Silicon’s positive charge and high ζ …See details»
Promising Results in Phase 2 Trial of ProSilic - Dermatology Times
Jun 10, 2024 SiSaf Ltd, a biopharmaceutical company based in the UK that has developed several bio-courier drug delivery technologies, announced positive topline results from a …See details»